Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1Advanced Malignant Solid Tumors 1

Interventions

fludarabine phosphate 60Cyclophosphamide 60Busulfan 43Cyclosporine 41Mycophenolic Acid 40Peripheral Blood Stem Cell Transplantation 39Cytarabine 36Whole-Body Irradiation 34Antilymphocyte Serum 29Filgrastim 26Tacrolimus 24Methotrexate 24fludarabine 23Cord Blood Stem Cell Transplantation 22Radiotherapy 21Melphalan 20Etoposide 18Methylprednisolone 15Azacitidine 14Granulocyte Colony-Stimulating Factor 13Idarubicin 12Daunorubicin 11Thiotepa 10sargramostim 8Cyclosporins 8Clofarabine 7Arsenic Trioxide 7Transplantation 6Topotecan 6Mitoxantrone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia, Refractory, with Excess of Blasts × TAK-243 × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡